Basic science

4MO - Preclinical evaluation of novel CDK4/6 inhibitor GLR2007 in breast and lung cancer models

Lei Yin, et al. 


In a number of tumor cell lines, GLR2007 inhibited proliferation at lower IC50 values compared to abemaciclib. GLR2007 demonstrated significant antitumor efficacy in xenograft models compared to vehicle controls. These preclinical studies demonstrate the potential of GLR2007 as a novel CDK4/6 inhibitor for the treatment of breast and lung cancer.


5MO - CDK4/6 blockade is as effective as immune-checkpoint inhibition in tumor growth control of Mlh1-/- and Msh2loxP/loxP villin-Cre mice

Inken Salewski, et al.  


While ICI-based therapies are effective and FDA approved for dMMR cancer, abemaciclib constitutes a promising alternative therapy option. The strong immune stimulation upon abemaciclib treatment renders this compound ideal for ICI-refractory or intrinsically resistant tumors.


6MO - PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways

Vincenzo Quagliariello, et al. 


We demonstrated, for the first time, that the PCSK9 inhibitor evolocumab exerts direct effects in cardiomyocytes during doxorubicin and trastuzumab exposure turning on a new light on its possible use in cancer patients.


7MO - Effect of anti-CTLA-4 immunotherapy on lymphocyte subset and activation profiles and clonal composition on the B16F0 mouse melanoma model

Diana V. Yuzhakova, et al. 


We found that anti-CTLA-4 immunotherapy leads to activation and clonal expansion of lymphocytes with similar TCRs. For detailed analysis, we developed the approach to identify the TCR specificity to specific B16F0 peptides.


1801MO - Neutrophils are associated with resistance to anti-PD-1 monotherapy in mismatch repair-deficient tumors

Laetitia Nebot, et al.   


Accumulation of neutrophils is associated with resistance to αPD-1 monotherapy in MMRD tumors. We propose that αPD- 1+αCTLA-4 combination may represent an effective strategy in patients with abnormal neutrophil accumulation.


1802MO - Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort

Letizia Gnetti, et al.  


Our data suggest that CRT may induce an enrichment of CD8+ T lymphocytes and this translates in better response to CRT. The new frontier of best treatment could be the use of specific immune cells (T lymphocytes) to trigger the system's immune response against disease.